Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in Germany / NCT06543823
Recruiting Not applicable

SUPRATHEL 250 as a Treatment for Oropharyngeal Wounds

NCT06543823 · tracked via the Priya Life Science Germany tracker
Sponsor
Alaa Emara
Phase
Not applicable
Started
2025-04-30
Last updated
2026-07-27

Condition(s) studied

TonsillitisTonsillectomyTonsillitis Recurrent

Investigational drug(s) / intervention(s)

Suprathel 250Comparator

Suprathel 250: The membrane is placed onto the wound bed and fixed in place by resorbable interrupted sutures.

Comparator: no membrane is placed onto the wound bed , left bare to heal

Study summary

To assess the use of Suprathel 250 for mucosal reconstruction in oropharyngeal defects. The membrane will be applied after tonsillectomy procedures and compared to bare wounds' healing

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
Accepted
* Indication for tonsillectomy according to the applicable clinical guideline. * Male or female patients aged 18 years or older. * Ability to understand the study information and provide written informed consent.

Primary outcome measure(s)

  • Pain Intensity (VAS) — postoperative day 0, 1, 2, 3, 4, 5, 7 and 10
    Visual Analogue Scores (0-10; 0 lowest , 10 highest)

Trial sites (1)

FacilityCityRegionStatus
Vinzenz von Paul Kliniken gGmbH Marienhospital Stuttgart Stuttgart Baden-Wurttemberg Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06543823 on ClinicalTrials.gov ↗ ← All trials in Germany